Bryan Johnson's Longevity Protocol: The Evidence Base Behind Blueprint

Who Is Bryan Johnson and What Is Blueprint?

Bryan Johnson is a technology entrepreneur who sold Braintree to PayPal in 2013 for $800 million and subsequently founded Kernel (brain-computer interfaces) and OS Fund. Since approximately 2021, he has publicly documented what he calls Blueprint: a self-experiment in which he attempts to minimize his biological age using a team of more than 30 physicians, continuous biomarker monitoring, and a fully systematized daily protocol covering nutrition, sleep, exercise, light exposure, and a large pharmaceutical plus supplement stack.

Johnson publishes protocol details, biomarker data, and research commentary at blueprint.bryanjohnson.com and through peer-reviewed correspondence. A 2024 letter in Aging (co-authored with his physician team) reported improvements across multiple aging biomarkers, including speed of aging measured by the DunedinPACE epigenetic clock.

The protocol is explicitly framed as an n-of-1 experiment. It is not a clinical trial. That distinction matters when evaluating the evidence.

The Prescription Drug Layer

Rapamycin

Rapamycin (sirolimus) is the most-cited longevity drug in Blueprint. It inhibits mTORC1, a nutrient-sensing complex that regulates cellular growth, autophagy, and senescence. Johnson has publicly stated he takes rapamycin weekly at doses reported to be in the 13 mg range, pulsed rather than continuous.

The strongest evidence comes from the Interventions Testing Program (ITP), an NIA-funded multi-site mouse aging trial. ITP data published in Aging Cell showed that rapamycin extended median lifespan in genetically heterogeneous mice by 23% in males and 26% in females when started at 600 days of age (equivalent to late middle age in humans) [1]. The magnitude is among the largest of any pharmacological intervention ever tested in mammals.

Human data are substantially thinner. Rapamycin is FDA-approved as an immunosuppressant for organ transplant recipients. A 2014 study in Science Translational Medicine (N=218, elderly volunteers) showed that everolimus, an mTOR inhibitor analogous to rapamycin, improved influenza vaccine response and reduced PD-1 expression on T cells at low weekly doses [2]. This suggested an immunosenescence benefit. No phase 3 human RCT has yet tested rapamycin for longevity as a primary endpoint.

Side effects at immunosuppressive doses include impaired wound healing, dyslipidemia, and infection risk. Whether intermittent low-dose pulsing (the Johnson approach) avoids these risks is under active investigation. The PEARL trial (NCT04488601) is currently evaluating oral rapamycin 5 mg/week in healthy aging adults; results are pending.

Metformin

Metformin (1,500 mg/day in Johnson's reported stack) activates AMPK, reduces hepatic glucose output, and may reduce mTORC1 signaling. It is FDA-approved for type 2 diabetes. Johnson does not have type 2 diabetes; he uses it off-label for longevity.

Observational data are compelling. A 2014 analysis in Diabetes Care found that type 2 diabetic patients on metformin lived longer than matched non-diabetic controls not taking metformin (adjusted HR 0.85, 95% CI 0.81-0.90) [3]. The TAME (Targeting Aging with Metformin) trial, an NIH-funded phase 3 RCT (N=3,000 planned), is testing metformin 1,500 mg/day against placebo in non-diabetic adults aged 65-79. Results are expected around 2028 [4].

A relevant concern from the MILES trial: metformin blunted the mitochondrial and gene-expression adaptations to exercise in older adults, raising a question about whether combining intensive training with daily metformin is counterproductive [5].

Acarbose

Acarbose is an alpha-glucosidase inhibitor that slows intestinal carbohydrate absorption, blunting postprandial glucose spikes. ITP mouse data showed acarbose extended median lifespan by 22% in males and 5% in females [6]. Johnson has cited this differential sex response as a limitation of direct translation to his protocol.

Human evidence for acarbose as a longevity drug is sparse. Its FDA approval is for type 2 diabetes management. The drug's longevity mechanism in mice likely involves reduced glycemic variability; whether the same effect size occurs in a non-diabetic human eating a 100% whole-food plant-based diet (already a low glycemic load) is uncertain.

Tadalafil and Other Cardiovascular Agents

Johnson reportedly takes tadalafil 5 mg daily. Tadalafil is a PDE5 inhibitor FDA-approved for erectile dysfunction and benign prostatic hyperplasia. Emerging research suggests PDE5 inhibitors may have endothelial and cardiovascular benefits independent of sexual function. A 2022 observational study in JACC (N=29,395) found daily PDE5 inhibitor use in men with erectile dysfunction was associated with a 25% lower risk of all-cause mortality over a median 9-year follow-up [7]. That association is hypothesis-generating, not causal.

The Supplement Stack

NMN and NAD+ Precursors

Johnson takes nicotinamide mononucleotide (NMN) 2,000 mg/day. NMN is a precursor to NAD+, a coenzyme that declines with aging and is required for sirtuins, PARP DNA repair enzymes, and mitochondrial function.

A 2023 randomized trial published in Nature Aging (N=80 healthy middle-aged adults) found NMN 300 mg/day for 60 days raised whole-blood NAD+ levels by approximately 38% vs. Baseline compared to 0.1% in placebo (P<0.001) [8]. Whether raising NAD+ translates into clinically meaningful longevity outcomes in humans is not yet established by prospective RCT data.

Lithium (Low-Dose)

Johnson takes lithium orotate at a very low dose (approximately 1 mg/day). Epidemiological data from a 2017 study in European Neuropsychopharmacology found that regions with higher natural lithium levels in drinking water had lower all-cause mortality rates [9]. The biological mechanism proposed involves GSK-3 inhibition and autophagy induction. This is association data only.

Lycopene, Lutein, and Carotenoids

Johnson takes lycopene 30 mg/day and lutein 25 mg/day. The Age-Related Eye Disease Study 2 (AREDS2, N=4,203) found that lutein/zeaxanthin supplementation reduced progression to advanced AMD by 26% over 5 years compared to placebo [10]. This is one of the stronger human RCT foundations in the entire Blueprint supplement list.

Additional Compounds

The stack includes alpha-lipoic acid, spermidine, fisetin, quercetin, CoQ10, magnesium threonate, glucosamine sulfate, and dozens more. For most, the primary longevity evidence is either cell-culture data, short-duration human pharmacokinetic studies, or ITP mouse results. Spermidine has a 2021 randomized pilot trial in older adults (N=100) showing improved memory performance at 1.2 mg/day over 12 months [11], but that is a cognitive endpoint, not lifespan.

The Lifestyle Interventions: Where Evidence Is Strongest

Caloric Restriction and Diet

Johnson eats approximately 1,977 kcal/day (his own published figure) across two to three meals, all plant-based, with a fasting window ending by 11 a.m. The CALERIE-2 trial (N=218 non-obese adults, 24 months) found that 11.9% sustained caloric restriction produced significant reductions in cardiometabolic risk factors, including a 4.2 mmHg drop in systolic blood pressure and improvements in LDL, HDL, and insulin sensitivity [12]. The effect of severe long-term caloric restriction on human lifespan itself has not been tested in an RCT, for obvious reasons.

The Okinawan dietary pattern and data from the PREDIMED trial (N=7,447) support Mediterranean-style plant-rich diets in reducing cardiovascular mortality; PREDIMED showed a 30% relative risk reduction in major cardiovascular events [13]. Johnson's diet is more restrictive than these patterns, and direct comparative RCT data do not exist.

Exercise

One hour of daily structured training, including resistance training and Zone 2 cardio, is among the most evidence-supported elements of Blueprint. A 2022 meta-analysis in British Journal of Sports Medicine (43 prospective cohort studies, N=1,116,229 participants) found that the highest physical activity levels were associated with a 35% lower all-cause mortality risk vs. The lowest levels [14]. Resistance training specifically showed a dose-response benefit up to 130-140 minutes per week, after which marginal gains flattened.

VO2 max is the fitness metric Johnson tracks most closely. Data from the Cooper Center Longitudinal Study showed that low cardiorespiratory fitness (CRF) conferred a higher hazard ratio for all-cause mortality than smoking, diabetes, or hypertension in men followed for a median 30 years [15].

Sleep

Johnson targets 8 hours 28 minutes of sleep per night and tracks it with an Oura Ring. The CDC recommends 7 or more hours of sleep for adults. A 2019 analysis in Nature Communications (N=500,000 UK Biobank participants) found that both short sleep (<6 hours) and long sleep (>9 hours) were associated with higher all-cause mortality, with the lowest mortality in those sleeping 7-8 hours [16]. Johnson's target sits within the optimal range. The evidence for optimizing sleep as a longevity intervention is solid at the epidemiological level; interventional sleep extension RCTs in healthy adults are rare.

Light Exposure and Circadian Rhythm

Johnson exposes himself to morning bright light within 5 minutes of waking and avoids artificial light after sunset. Research from the Salk Institute published in Cell Metabolism demonstrated that time-restricted feeding combined with circadian-aligned light exposure improved metabolic parameters in animal models [17]. Human circadian intervention data are growing; a 2022 trial in JAMA Internal Medicine (N=84) found that circadian-aligned eating (earlier meals) reduced 24-hour glucose area under the curve by 8.6% vs. Late eating (P<0.01) [18].

Biomarker Monitoring and the Measurement Infrastructure

A distinctive feature of Blueprint is the frequency of testing. Johnson reportedly undergoes monthly or quarterly panels covering 100+ biomarkers, including epigenetic age clocks (Horvath, DunedinPACE), inflammatory markers (hsCRP, IL-6), metabolomics, microbiome sequencing, DEXA body composition, coronary artery calcium scoring, continuous glucose monitoring, and full-body MRI.

The DunedinPACE clock measures the speed of biological aging rather than a fixed age estimate. A score below 1.0 means aging is slower than the population average pace of 1 year of biological aging per calendar year. Johnson has publicly reported a DunedinPACE score of approximately 0.69, meaning his cells appear to be aging at 69% of the expected rate. The clock's development and validation were published in eLife in 2022 [19].

Frequent biomarker monitoring creates an important feedback loop: it allows protocol adjustment based on objective data rather than symptom-based guessing. This principle aligns with precision medicine frameworks being tested in programs such as the Human Longevity Project and Stanford's 100K Wellness Project.

The limitation is that biomarker surrogates are not the same as hard clinical endpoints (years of life, disability-free survival). A lower DunedinPACE score is associated with lower mortality risk in population studies; it does not guarantee Johnson personally will live longer.

What the Protocol Gets Right and Where Gaps Remain

Interventions with Strong Human Evidence

• Daily vigorous exercise (35-40% relative risk reduction in all-cause mortality in meta-analyses [14])
• Caloric restriction within non-deficient ranges (CALERIE-2 cardiometabolic benefits [12])
• 7-8 hours of quality sleep (lowest mortality band in UK Biobank [16])
• Mediterranean-style whole food diet (PREDIMED 30% cardiovascular event reduction [13])
• AREDS2-supported carotenoid supplementation for eye health [10]

Interventions with Moderate but Incomplete Human Evidence

• Metformin off-label: strong observational signal, TAME trial pending [4]
• PDE5 inhibitor cardiovascular association: observational only [7]
• NMN NAD+ restoration: demonstrated in short-term RCTs, longevity endpoints unproven [8]

Interventions Resting Primarily on Animal Data

• Rapamycin longevity extension: ITP mouse data compelling [1], human longevity RCT absent
• Acarbose lifespan extension: ITP mouse data [6], human longevity data absent
• Spermidine, fisetin, quercetin, alpha-ketoglutarate: mostly preclinical or very early human data

The American Federation for Aging Research has stated in its TAME trial documentation: "Metformin is the first drug that will be tested in a large-scale clinical trial for its ability to delay aging and prevent age-related conditions in people who do not have the diseases the drug normally treats" [4]. That framing captures the current status of the entire longevity pharmacology field: promising, early, and not yet proven in humans at the endpoint level that matters.

Regulatory and Safety Considerations

None of the longevity uses of rapamycin, metformin, or acarbose described above are FDA-approved indications. Physicians prescribing these drugs off-label for healthy adults carry significant clinical judgment responsibility. Rapamycin's immunosuppressive effects at high doses are well-documented; whether weekly 13 mg pulsing in a healthy adult confers meaningful infection risk is genuinely unknown, and patients considering this approach should have full infectious disease and baseline immune workup.

Johnson has been transparent that his protocol requires continuous physician supervision. Attempting to replicate any part of it without qualified clinical oversight carries real risk, particularly for rapamycin, which has a narrow therapeutic index at immunosuppressive doses.

The FDA's current position, as stated in multiple warning letters regarding NMN and similar compounds marketed with disease claims, is that no dietary supplement is approved to treat, cure, or prevent any disease including aging-related conditions [20].